Report cover image

Global Influenza NA Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 180 Pages
SKU # APRC20356574

Description

Summary

According to APO Research, The global Influenza NA Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Influenza NA Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Influenza NA Inhibitor include ATK Chemical, Chemwill Asia Co.,Ltd., Green Cross, Moksha8 Pharma, NeoPharm, Shionogi Co., GlaxoSmithKline, Henan DaKen Chemical and Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Influenza NA Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Influenza NA Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza NA Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza NA Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Influenza NA Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Influenza NA Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Influenza NA Inhibitor Segment by Company

ATK Chemical
Chemwill Asia Co.,Ltd.
Green Cross
Moksha8 Pharma
NeoPharm
Shionogi Co.
GlaxoSmithKline
Henan DaKen Chemical
Roche
Influenza NA Inhibitor Segment by Type

Zanamivir
Peramivir
Oseltamivir
Influenza NA Inhibitor Segment by Application

Influenza A Treatment
Influenza B Treatment
Influenza NA Inhibitor Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza NA Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza NA Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza NA Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza NA Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Influenza NA Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Influenza NA Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

180 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Influenza NA Inhibitor Market Size, 2020 VS 2024 VS 2031
1.3 Global Influenza NA Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.4 Global Influenza NA Inhibitor Sales Estimates and Forecasts (2020-2031)
1.5 Global Influenza NA Inhibitor Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Influenza NA Inhibitor Market Dynamics
2.1 Influenza NA Inhibitor Industry Trends
2.2 Influenza NA Inhibitor Industry Drivers
2.3 Influenza NA Inhibitor Industry Opportunities and Challenges
2.4 Influenza NA Inhibitor Industry Restraints
3 Influenza NA Inhibitor Market by Manufacturers
3.1 Global Influenza NA Inhibitor Revenue by Manufacturers (2020-2025)
3.2 Global Influenza NA Inhibitor Sales by Manufacturers (2020-2025)
3.3 Global Influenza NA Inhibitor Average Sales Price by Manufacturers (2020-2025)
3.4 Global Influenza NA Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Influenza NA Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Influenza NA Inhibitor Manufacturers, Product Type & Application
3.7 Global Influenza NA Inhibitor Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Influenza NA Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 Influenza NA Inhibitor Players Market Share by Revenue in 2024
3.8.3 2024 Influenza NA Inhibitor Tier 1, Tier 2, and Tier 3
4 Influenza NA Inhibitor Market by Type
4.1 Influenza NA Inhibitor Type Introduction
4.1.1 Zanamivir
4.1.2 Peramivir
4.1.3 Oseltamivir
4.2 Global Influenza NA Inhibitor Sales by Type
4.2.1 Global Influenza NA Inhibitor Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Influenza NA Inhibitor Sales by Type (2020-2031)
4.2.3 Global Influenza NA Inhibitor Sales Market Share by Type (2020-2031)
4.3 Global Influenza NA Inhibitor Revenue by Type
4.3.1 Global Influenza NA Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Influenza NA Inhibitor Revenue by Type (2020-2031)
4.3.3 Global Influenza NA Inhibitor Revenue Market Share by Type (2020-2031)
5 Influenza NA Inhibitor Market by Application
5.1 Influenza NA Inhibitor Application Introduction
5.1.1 Influenza A Treatment
5.1.2 Influenza B Treatment
5.2 Global Influenza NA Inhibitor Sales by Application
5.2.1 Global Influenza NA Inhibitor Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Influenza NA Inhibitor Sales by Application (2020-2031)
5.2.3 Global Influenza NA Inhibitor Sales Market Share by Application (2020-2031)
5.3 Global Influenza NA Inhibitor Revenue by Application
5.3.1 Global Influenza NA Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Influenza NA Inhibitor Revenue by Application (2020-2031)
5.3.3 Global Influenza NA Inhibitor Revenue Market Share by Application (2020-2031)
6 Global Influenza NA Inhibitor Sales by Region
6.1 Global Influenza NA Inhibitor Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Influenza NA Inhibitor Sales by Region (2020-2031)
6.2.1 Global Influenza NA Inhibitor Sales by Region (2020-2025)
6.2.2 Global Influenza NA Inhibitor Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Influenza NA Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Influenza NA Inhibitor Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Influenza NA Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Influenza NA Inhibitor Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Influenza NA Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Influenza NA Inhibitor Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Influenza NA Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Influenza NA Inhibitor Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Influenza NA Inhibitor Revenue by Region
7.1 Global Influenza NA Inhibitor Revenue by Region
7.1.1 Global Influenza NA Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Influenza NA Inhibitor Revenue by Region (2020-2025)
7.1.3 Global Influenza NA Inhibitor Revenue by Region (2026-2031)
7.1.4 Global Influenza NA Inhibitor Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Influenza NA Inhibitor Revenue (2020-2031)
7.2.2 North America Influenza NA Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Influenza NA Inhibitor Revenue (2020-2031)
7.3.2 Europe Influenza NA Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Influenza NA Inhibitor Revenue (2020-2031)
7.4.2 Asia-Pacific Influenza NA Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Influenza NA Inhibitor Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Influenza NA Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 ATK Chemical
8.1.1 ATK Chemical Comapny Information
8.1.2 ATK Chemical Business Overview
8.1.3 ATK Chemical Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
8.1.5 ATK Chemical Recent Developments
8.2 Chemwill Asia Co.,Ltd.
8.2.1 Chemwill Asia Co.,Ltd. Comapny Information
8.2.2 Chemwill Asia Co.,Ltd. Business Overview
8.2.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
8.2.5 Chemwill Asia Co.,Ltd. Recent Developments
8.3 Green Cross
8.3.1 Green Cross Comapny Information
8.3.2 Green Cross Business Overview
8.3.3 Green Cross Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Green Cross Influenza NA Inhibitor Product Portfolio
8.3.5 Green Cross Recent Developments
8.4 Moksha8 Pharma
8.4.1 Moksha8 Pharma Comapny Information
8.4.2 Moksha8 Pharma Business Overview
8.4.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
8.4.5 Moksha8 Pharma Recent Developments
8.5 NeoPharm
8.5.1 NeoPharm Comapny Information
8.5.2 NeoPharm Business Overview
8.5.3 NeoPharm Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 NeoPharm Influenza NA Inhibitor Product Portfolio
8.5.5 NeoPharm Recent Developments
8.6 Shionogi Co.
8.6.1 Shionogi Co. Comapny Information
8.6.2 Shionogi Co. Business Overview
8.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
8.6.5 Shionogi Co. Recent Developments
8.7 GlaxoSmithKline
8.7.1 GlaxoSmithKline Comapny Information
8.7.2 GlaxoSmithKline Business Overview
8.7.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
8.7.5 GlaxoSmithKline Recent Developments
8.8 Henan DaKen Chemical
8.8.1 Henan DaKen Chemical Comapny Information
8.8.2 Henan DaKen Chemical Business Overview
8.8.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
8.8.5 Henan DaKen Chemical Recent Developments
8.9 Roche
8.9.1 Roche Comapny Information
8.9.2 Roche Business Overview
8.9.3 Roche Influenza NA Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Roche Influenza NA Inhibitor Product Portfolio
8.9.5 Roche Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Influenza NA Inhibitor Value Chain Analysis
9.1.1 Influenza NA Inhibitor Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Influenza NA Inhibitor Production Mode & Process
9.2 Influenza NA Inhibitor Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Influenza NA Inhibitor Distributors
9.2.3 Influenza NA Inhibitor Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.